Effect of gamma-vinyl GABA in tardive dyskinesia

Søren Korsgaard; Daniel E. Casey; Jes Gerlach

doi:10.1016/0165-1781(83)90014-8

Effect of gamma-vinyl GABA in tardive dyskinesia

Søren Korsgaard
, Daniel E. Casey
, Jes Gerlach

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.

Original language	English (US)
Pages (from-to)	261-269
Number of pages	9
Journal	Psychiatry Research
Volume	8
Issue number	4
DOIs	https://doi.org/10.1016/0165-1781(83)90014-8
State	Published - Apr 1983
Externally published	Yes

Funding

Acknowledgments. This study was supported by the Danish Foundation for the Advancement of Medical Science (video equipment). Centre de Recherche Merrell International, Strasbourg. France, supplied the GVG. Tilli Wanstrup provided technical assistance.

Funders
Danish Foundation for the Advancement of Medical Science

Keywords

parkinsonism
tardive dyskinesia
γ-Vinyl GABA

ASJC Scopus subject areas

Psychiatry and Mental health
Biological Psychiatry

Access to Document

10.1016/0165-1781(83)90014-8

Cite this

@article{d71e98a456744207a6235a22fb07ea9f,

title = "Effect of gamma-vinyl GABA in tardive dyskinesia",

abstract = "γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.",

keywords = "parkinsonism, tardive dyskinesia, γ-Vinyl GABA",

author = "S{\o}ren Korsgaard and Casey, \{Daniel E.\} and Jes Gerlach",

note = "Funding Information: Acknowledgments. This study was supported by the Danish Foundation for the Advancement of Medical Science (video equipment). Centre de Recherche Merrell International, Strasbourg. France, supplied the GVG. Tilli Wanstrup provided technical assistance.",

year = "1983",

month = apr,

doi = "10.1016/0165-1781(83)90014-8",

language = "English (US)",

volume = "8",

pages = "261--269",

journal = "Psychiatry Research",

issn = "0165-1781",

publisher = "Elsevier Ireland Ltd",

number = "4",

}

TY - JOUR

T1 - Effect of gamma-vinyl GABA in tardive dyskinesia

AU - Korsgaard, Søren

AU - Casey, Daniel E.

AU - Gerlach, Jes

N1 - Funding Information: Acknowledgments. This study was supported by the Danish Foundation for the Advancement of Medical Science (video equipment). Centre de Recherche Merrell International, Strasbourg. France, supplied the GVG. Tilli Wanstrup provided technical assistance.

PY - 1983/4

Y1 - 1983/4

N2 - γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.

AB - γ-Vinyl GABA (γ-aminobutyric acid), a drug that increases brain GABA via GABA transaminase inhibition, was evaluated in a blind, placebo-controlled trial in 10 patients with stable tardive dyskinesia. Drug effects during active treatment (2 to 6 g/day) and during pre- and posttreatment placebo periods were determined by scoring randomly sequenced videotapes of tardive dyskinesia and parkisonian symptoms recorded weekly during standardized examinations. Tardive dyskinesia was significantly reduced, and correlated to increased parkinsonism. Eye blinking rates decreased, but psychiatric symptoms were unchanged during treatment.

KW - parkinsonism

KW - tardive dyskinesia

KW - γ-Vinyl GABA

UR - https://www.scopus.com/pages/publications/0020522189

UR - https://www.scopus.com/pages/publications/0020522189#tab=citedBy

U2 - 10.1016/0165-1781(83)90014-8

DO - 10.1016/0165-1781(83)90014-8

M3 - Article

C2 - 6136054

AN - SCOPUS:0020522189

SN - 0165-1781

VL - 8

SP - 261

EP - 269

JO - Psychiatry Research

JF - Psychiatry Research

IS - 4

ER -

Effect of gamma-vinyl GABA in tardive dyskinesia

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this